GENERAL ENQUIRIES: Tel: + 27 12 841 2911 | Email: callcentre@csir.co.za

Show simple item record

dc.contributor.author Ngwane, AH
dc.contributor.author Panayides, Jenny-Lee
dc.contributor.author Chouteau, F
dc.contributor.author Macingwana, L
dc.contributor.author Viljoen, A
dc.contributor.author Baker, B
dc.contributor.author Madikane, E
dc.contributor.author De Kock, C
dc.contributor.author Wiesner, L
dc.contributor.author Chibale, K
dc.contributor.author Parkinson, CJ
dc.contributor.author Mmutlane, EM
dc.contributor.author Van Helden, P
dc.contributor.author Wiid, I
dc.date.accessioned 2017-01-17T08:52:34Z
dc.date.available 2017-01-17T08:52:34Z
dc.date.issued 2016-01
dc.identifier.citation Ngwane, A.H., Panayides, J.L., Chouteau, F., Macingwana, L., Viljoen, A., Baker, B., Madikane, E., De Kock, C., Wiesner, L., Chibale, K., Parkinson, C.J., Mmutlane, E.M., Van Helden, P. and Wiid, I. 2016. Design, synthesis, and in vitro antituberculosis activity of 2(5H)-Furanone derivatives. International Union of Biochemistry and Molecular Biology Life. 68, pp. 612-620. en_US
dc.identifier.issn 1521-6543
dc.identifier.uri doi: 10.1002/iub.1526
dc.identifier.uri http://www.ncbi.nlm.nih.gov/pubmed/27346745
dc.identifier.uri http://hdl.handle.net/10204/8910
dc.description Copyright:2016 Wiley Online Library:Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website. The definitive version of the work is published in the International Union of Biochemistry and Molecular Biology Life.68,pp. 612-20. en_US
dc.description.abstract A series of 2(5H)-furanone-based compounds were synthesized from commercially available mucohalic acids. From the first-generation compounds, three showed inhibitory activity (10 µg/mL) of at least 35% against Mycobacterium smegmatis mc(2) 155 growth (Bioscreen C system). In screening the active first-generation compounds for growth inhibition against Mycobacterium tuberculosis H37Rv, the most active compound was identified with a minimum inhibitory concentration (MIC99 ) of 8.07 µg/mL (15.8 µM) using BACTEC 460 system. No cross-resistance was observed with some current first-line anti-TB drugs, since it similarly inhibited the growth of multidrug resistant (MDR) clinical isolates. The compound showed a good selectivity for mycobacteria since it did not inhibit the growth of selected Gram-positive and Gram-negative bacteria. It also showed synergistic activity with rifampicin (RIF) and additive activity with isoniazid (INH) and ethambutol (EMB). Additional time-kill studies showed that the compound is bacteriostatic to mycobacteria, but cytotoxic to the Chinese Hamster Ovarian (CHO) cell line. From a second generation library, two compounds showed improved anti-TB activity against M. tuberculosis H37Rv and decreased CHO cell cytotoxicity. The compounds exhibited MIC values of 2.62 µg/mL (5.6 µM) and 3.07 µg/mL (5.6 µM) respectively. The improved cytotoxicity against CHO cell line of the two compounds ranged from IC50 = 38.24 µg/mL to IC50 =45.58 µg/mL when compared to the most active first-generation compound (IC50 =1.82 µg/mL).The two second generation leads with selectivity indices (SI) of 14.64 and 14.85 respectively, warrant further development as anti-TB drug candidates. en_US
dc.language.iso en en_US
dc.publisher Wiley Online Library en_US
dc.relation.ispartofseries Workflow;17443
dc.subject Antimycobacterial en_US
dc.subject Furanone en_US
dc.subject Cytotoxicity en_US
dc.subject Synergy en_US
dc.title Design, synthesis, and in vitro antituberculosis activity of 2(5H)-Furanone derivatives en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ResearchSpace


Advanced Search

Browse

My Account